Why IBS Awareness Month Matters
Every April, IBS Awareness Month draws attention to a condition that affects an estimated 10 to 15 percent of the global population — yet remains widely misunderstood, frequently dismissed, and for many people, maddeningly difficult to get clarity on. Irritable bowel syndrome is real, it is common, and its impact on daily life can be significant. But the path to diagnosis is rarely straightforward.
This April, the conversation is shifting. Rather than stopping at symptom lists and dietary tips, it’s worth asking a deeper question: what can objective biomarkers tell us about what’s happening in the gut?
The Prevalence and Impact of IBS
According to the International Foundation for Gastrointestinal Disorders (IFFGD), IBS affects people of all ages and backgrounds, with women diagnosed at roughly twice the rate of men. Symptoms — bloating, abdominal pain, unpredictable bowel habits — range from mildly inconvenient to profoundly disruptive. Many people with IBS report reduced quality of life, missed work, and social withdrawal as a result of their symptoms.
Despite how common IBS is, it remains underfunded in research and under-recognized in clinical settings. Many patients cycle through multiple appointments, repeated “normal” test results, and conflicting advice before arriving at a clear picture of what’s going on.
Why Diagnosis Often Takes Years
One of the most frustrating realities for people living with gut symptoms is the diagnostic delay. Research has suggested that IBS takes an average of six to seven years to diagnose — a span of time filled with uncertainty, self-doubt, and often unnecessary anxiety about what might be wrong.
Part of this delay stems from the nature of IBS itself: it’s a functional disorder, meaning it doesn’t produce the kind of visible structural changes that show up on standard imaging or routine bloodwork. But delay is also driven by a lack of awareness — among both patients and, sometimes, providers — about which biomarkers may help differentiate IBS from conditions that can look similar but require different management.
The Cost of Uncertainty
Beyond the physical discomfort, diagnostic uncertainty carries its own burden. Not knowing whether symptoms reflect a functional condition like IBS or something structural like inflammatory bowel disease (IBD) can fuel anxiety, drive unnecessary dietary restriction, and lead to decisions made without adequate information. Clarity — even partial clarity — matters. And increasingly, biomarker testing is helping provide it.
What Is IBS — and What It Isn’t
Understanding IBS begins with understanding what kind of condition it actually is — and separating it from the conditions it’s most often confused with.
Rome IV Criteria Explained
IBS is diagnosed clinically, using symptom-based criteria rather than a single defining lab test. The current standard is the Rome IV criteria, developed by an international body of gastroenterology experts. Under these criteria, IBS is characterized by recurrent abdominal pain — at least one day per week on average — associated with changes in stool frequency, changes in stool form or appearance, or a relationship to defecation.
Importantly, these symptoms must have been present for the last three months, with onset at least six months before diagnosis. Subtypes (IBS-D for diarrhea-predominant, IBS-C for constipation-predominant, and IBS-M for mixed) help clinicians understand the pattern and guide management.
Functional Disorder vs Structural Disease
The distinction between a “functional” and a “structural” disorder is one that confuses many people — partly because “functional” has sometimes been used dismissively to imply that symptoms aren’t real. They are real. What “functional” actually means is that the gut’s structure appears intact, but its function — how it moves, senses, and responds — is altered.
In contrast, structural or inflammatory diseases like Crohn’s disease or ulcerative colitis involve measurable changes to the intestinal lining that can be detected through endoscopy, imaging, or certain biomarkers. This distinction matters because the management pathways are different — and biomarkers can help clarify which path applies.
The Gut-Brain Axis Connection
A growing body of research highlights the role of the gut-brain axis — the bidirectional communication network between the central nervous system and the gastrointestinal tract — in IBS. Stress, anxiety, and trauma can directly influence gut motility and sensitivity. Conversely, gut discomfort can amplify psychological distress. This isn’t a reason to dismiss IBS as “all in your head.” It’s a reason to understand it as a complex, whole-body condition that warrants thoughtful, multifaceted evaluation.
IBS vs IBD: Why Biomarkers Matter
One of the most common concerns for people experiencing chronic gut symptoms is distinguishing IBS from inflammatory bowel disease — a group of conditions that includes Crohn’s disease and ulcerative colitis. The two can share surface-level symptoms, but they are fundamentally different in nature, and treating one as the other can have real consequences.
This is where specific biomarkers become genuinely valuable — not as diagnostic tools in isolation, but as data points that can help shape the clinical conversation.
Fecal Calprotectin — Marker of Intestinal Inflammation
Fecal calprotectin is a protein released by white blood cells (neutrophils) when inflammation is present in the intestinal wall. It is measured through a stool sample and can reflect the degree of intestinal inflammation more directly than most blood tests.
In people with active IBD, fecal calprotectin levels tend to be elevated. In people with IBS — where the gut is functionally disrupted but not inflamed in the same structural way — levels are typically within normal range. This makes calprotectin one of the more useful non-invasive tools available for helping differentiate between the two conditions.
It’s worth noting that calprotectin levels can also be elevated by other factors, including non-steroidal anti-inflammatory drug use, infection, and certain other GI conditions. A result outside the reference range warrants discussion with a healthcare provider rather than a self-directed conclusion.
CRP and ESR — Systemic Inflammation Signals
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are blood-based markers of systemic inflammation — inflammation occurring throughout the body rather than in one specific location. Both are commonly used in general health monitoring and can be informative in the context of gut symptoms.
Elevated CRP or ESR can be associated with active inflammation and may prompt a provider to investigate further for conditions like IBD or other inflammatory conditions. In uncomplicated IBS, these markers are generally within normal range — though it’s important to understand that normal results don’t automatically confirm IBS, and elevated results don’t automatically indicate IBD.
These markers are broad signals, not specific to the gut. Their value lies in providing additional context alongside symptom history and other findings.
When to Screen for Celiac Disease (tTG Antibodies)
Celiac disease is an autoimmune condition triggered by gluten in which the immune system attacks the lining of the small intestine. Its symptoms — bloating, diarrhea, abdominal discomfort — can closely mimic IBS, and it is estimated that a meaningful proportion of people diagnosed with IBS may have undetected celiac disease.
The most commonly used initial screening marker is anti-tissue transglutaminase IgA (tTG-IgA), a blood test that detects an antibody produced in response to gluten. Elevated tTG-IgA levels can indicate a need for further evaluation, typically including small intestinal biopsy for confirmation.
Importantly, celiac screening should be done while the person is still consuming gluten — removing gluten from the diet before testing can produce a false-negative result. Anyone considering a gluten-free diet as a symptom management strategy should discuss celiac screening with their provider beforehand.
Why “Normal Tests” Don’t Always End the Story
A common source of frustration in the diagnostic process is being told that lab results are “normal” — while symptoms persist and no clear explanation is offered. Understanding why this happens can help reframe the experience.
Low-Grade Inflammation
Standard inflammation markers like CRP and ESR are most sensitive to significant inflammatory activity. Low-grade, subclinical inflammation — the kind that can be present in conditions like post-infectious IBS or early-stage gut disruption — may not register clearly on these tests. This doesn’t mean nothing is happening. It means the signal is subtle and may require more targeted investigation or longitudinal monitoring.
Post-Infectious IBS
A subset of IBS cases appear to be triggered by a gastrointestinal infection — a phenomenon known as post-infectious IBS. Following gastroenteritis caused by bacteria, viruses, or parasites, some individuals develop persistent gut symptoms that meet the criteria for IBS. The infection may have cleared, and standard labs may appear normal, yet the gut’s function remains altered. Understanding this pathway helps contextualize why “normal” results don’t always reflect a complete absence of underlying disruption.
Microbiome Disruption
The gut microbiome — the complex community of microorganisms living in the digestive tract — plays a significant role in gut function, immune regulation, and even mood. Dysbiosis, or an imbalance in the microbiome’s composition, has been associated with IBS symptoms in some research. Comprehensive stool analysis can offer insight into microbial diversity, the presence of pathogens or parasites, and markers of digestive function. While this area of science is still evolving, it represents an additional layer of data for those seeking a fuller picture.
Proactive Gut Monitoring
For people navigating chronic or recurring gut symptoms, proactive monitoring — rather than waiting for symptoms to escalate — represents a meaningful shift in how to approach gut health.
When Inflammatory Testing May Be Informative
Biomarker testing may be worth exploring if you have experienced persistent bloating, abdominal pain, or changes in bowel habits for more than a few weeks; if you have been told your standard labs are normal but symptoms continue; if you have a family history of IBD or celiac disease; if your symptoms changed significantly following a gastrointestinal illness; or if you are considering a significant dietary change, such as a low-FODMAP elimination protocol, and want a baseline before you begin.
These scenarios are not exhaustive, and testing is not a substitute for evaluation by a qualified provider — particularly if you are experiencing alarm symptoms such as blood in your stool, significant unintentional weight loss, fever, or nocturnal symptoms that wake you from sleep. These warrant prompt medical attention.
Understanding Stool and Blood Panels
Direct-to-consumer (DTC) lab testing services like Everlywell and DirectLabs have expanded access to a range of gastrointestinal and inflammatory biomarkers without requiring a physician’s referral in many states. Panels can include fecal calprotectin, CRP, celiac antibody screening, CBC, and CMP — providing informational data that can be shared with a gastroenterologist or primary care provider.
The value of these services lies in their accessibility during periods of diagnostic delay, and in giving individuals more structured information to bring into clinical conversations. They are not a replacement for colonoscopy, imaging, or clinical examination — but they can help move the conversation forward.
Tracking Biomarkers During Diet or Stress Changes
One practical application of biomarker monitoring is tracking changes over time. If you are beginning a low-FODMAP elimination diet, increasing fiber, or making other dietary adjustments, follow-up testing several months later can provide insight into whether those changes are influencing your inflammatory markers or overall gut health. This turns dietary experimentation into something more measurable — replacing guesswork with data.
Turning Awareness Into Action This April
IBS Awareness Month is an invitation to move from frustration toward clarity — and from passive symptom endurance toward informed, proactive engagement with your own gut health.
The “April Gut Check” Concept
Consider using April as a prompt to start a gut health conversation — with your doctor, a gastroenterologist, or through a baseline biomarker panel. Key questions worth exploring might include: Are my inflammation markers consistent with a functional condition? Have I ever been screened for celiac disease? Is there a pattern in my symptoms that correlates with specific dietary triggers or stress periods?
You don’t need to have all the answers before you start. A single biomarker result shared with a knowledgeable provider can open a door that years of vague symptom descriptions may not have.
Owning Your Gut Health Data
There is genuine power in having objective data about your own body. For the many people who have spent years being told their symptoms are stress-related, their tests are normal, or that IBS is “just something you live with,” biomarker data can reframe the conversation entirely — from dismissal to dialogue.
Your symptoms are real. Your questions deserve structured answers. And this IBS Awareness Month, the tools to start seeking those answers are more accessible than ever.
This article is intended for general educational purposes only and does not constitute medical advice. Biomarkers can provide informational insight but are not a substitute for clinical diagnosis or medical evaluation. IBS is diagnosed using symptom-based criteria by a qualified healthcare provider. Please consult a licensed provider before making decisions about testing, dietary changes, or symptom management. If you are experiencing alarm symptoms, seek medical care promptly.
